Curis (CRIS) Shares Down 8.2%

Curis, Inc. (NASDAQ:CRIS) was down 8.2% on Tuesday . The stock traded as low as $0.56 and last traded at $0.56. Approximately 1,535,193 shares traded hands during mid-day trading, a decline of 20% from the average daily volume of 1,927,905 shares. The stock had previously closed at $0.61.

Several equities research analysts have recently weighed in on CRIS shares. Zacks Investment Research raised shares of Curis from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a research report on Tuesday, May 8th. Robert W. Baird dropped their target price on shares of Curis to $6.00 and set an “outperform” rating for the company in a research report on Monday, May 7th. Finally, ValuEngine raised shares of Curis from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $4.50.

The stock has a market capitalization of $93.53 million, a price-to-earnings ratio of -1.56 and a beta of 1.29. The company has a current ratio of 3.60, a quick ratio of 3.60 and a debt-to-equity ratio of 2.24.

Curis (NASDAQ:CRIS) last released its earnings results on Thursday, May 3rd. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.02. The company had revenue of $2.47 million during the quarter, compared to the consensus estimate of $2.30 million. Curis had a negative net margin of 472.13% and a negative return on equity of 247.46%. sell-side analysts anticipate that Curis, Inc. will post -0.37 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of Curis by 2.3% in the 4th quarter. BlackRock Inc. now owns 9,719,497 shares of the biotechnology company’s stock worth $6,803,000 after purchasing an additional 223,002 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Curis by 1,341.7% in the 4th quarter. Millennium Management LLC now owns 3,149,154 shares of the biotechnology company’s stock valued at $2,204,000 after buying an additional 2,930,725 shares during the period. Arnhold LLC acquired a new position in shares of Curis in the 1st quarter valued at about $1,907,000. GSA Capital Partners LLP boosted its holdings in shares of Curis by 104.2% in the 1st quarter. GSA Capital Partners LLP now owns 1,913,208 shares of the biotechnology company’s stock valued at $1,250,000 after buying an additional 976,151 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in shares of Curis by 2,389.5% in the 4th quarter. Renaissance Technologies LLC now owns 1,331,900 shares of the biotechnology company’s stock valued at $932,000 after buying an additional 1,278,400 shares during the period. 45.83% of the stock is owned by institutional investors.

About Curis

Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply